164 related articles for article (PubMed ID: 32095892)
1. [Safety management of the treatment with antimalarial drugs in rheumatology. Interdisciplinary recommendations based on a systematic literature search].
Fiehn C; Ness T; Weseloh C; Specker C; Hadjiski D; Detert J; Krüger K;
Z Rheumatol; 2020 Mar; 79(2):186-194. PubMed ID: 32095892
[TBL] [Abstract][Full Text] [Related]
2. Safety management in treatment with antimalarials in rheumatology. Interdisciplinary recommendations on the basis of a systematic literature review.
Fiehn C; Ness T; Weseloh C; Specker C; Hadjiski D; Detert J; Krüger K;
Z Rheumatol; 2021 Feb; 80(Suppl 1):1-9. PubMed ID: 32236844
[TBL] [Abstract][Full Text] [Related]
3. [Chloroquine retinopathy].
Nguyen AL; Tan AN; Lavrijsen APM
Ned Tijdschr Geneeskd; 2018 Dec; 163():. PubMed ID: 30570930
[TBL] [Abstract][Full Text] [Related]
4. Long-term effectiveness of antimalarial drugs in rheumatic diseases.
Aviña-Zubieta JA; Galindo-Rodriguez G; Newman S; Suarez-Almazor ME; Russell AS
Ann Rheum Dis; 1998 Oct; 57(10):582-7. PubMed ID: 9893568
[TBL] [Abstract][Full Text] [Related]
5. Identification of new risk factors for hydroxychloroquine and chloroquine retinopathy in systemic lupus erythematosus patients.
Trefond L; Lhote R; Mathian A; de Chambrun MP; Pha M; Hie M; Miyara M; Papo M; Moyon Q; Taieb D; Saade S; Salem TB; Haroche J; Chasset F; Aubart FC; Zahr N; Amoura Z
Semin Arthritis Rheum; 2024 Jun; 66():152417. PubMed ID: 38394986
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of toxic retinopathy caused by antimalarial medications with spectral domain optical coherence tomography.
Cabral RTS; Klumb EM; Couto MINN; Carneiro S
Arq Bras Oftalmol; 2019; 82(1):12-17. PubMed ID: 30403262
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis.
Lenfant T; Salah S; Leroux G; Bousquet E; Le Guern V; Chasset F; Francès C; Morel N; Chezel J; Papo T; Cacoub P; Mouthon L; Guettrot-Imbert G; Cohen P; Régent A; Mauget-Faÿsse M; Piette JC; Jallouli M; Costedoat-Chalumeau N;
Rheumatology (Oxford); 2020 Dec; 59(12):3807-3816. PubMed ID: 32442312
[TBL] [Abstract][Full Text] [Related]
8. Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update.
Abdulaziz N; Shah AR; McCune WJ
Curr Opin Rheumatol; 2018 May; 30(3):249-255. PubMed ID: 29517495
[TBL] [Abstract][Full Text] [Related]
9. Discontinuation of antimalarial drugs in systemic lupus erythematosus.
Wang C; Fortin PR; Li Y; Panaritis T; Gans M; Esdaile JM
J Rheumatol; 1999 Apr; 26(4):808-15. PubMed ID: 10229401
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of hydroxychloroquine retinopathy with long-term use in a cohort of Indian patients with rheumatic diseases.
Manoj M; Sahoo RR; Singh A; Hazarika K; Bafna P; Kaur A; Wakhlu A
Rheumatol Int; 2021 May; 41(5):929-937. PubMed ID: 33704526
[TBL] [Abstract][Full Text] [Related]
11. American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity.
Desmarais J; Rosenbaum JT; Costenbader KH; Ginzler EM; Fett N; Goodman S; O'Dell J; Pineau CA; Schmajuk G; Werth VP; Link MS; Kovacs R
Arthritis Rheumatol; 2021 Dec; 73(12):2151-2160. PubMed ID: 34697918
[TBL] [Abstract][Full Text] [Related]
12. Guidelines on prescribing and monitoring antimalarials in rheumatic diseases: a systematic review.
Cramarossa G; Liu HY; Turk MA; Pope JE
Clin Exp Rheumatol; 2021; 39(2):407-412. PubMed ID: 33124575
[TBL] [Abstract][Full Text] [Related]
13. Hydroxychloroquine retinopathy.
Yusuf IH; Sharma S; Luqmani R; Downes SM
Eye (Lond); 2017 Jun; 31(6):828-845. PubMed ID: 28282061
[TBL] [Abstract][Full Text] [Related]
14. Improving eye screening practice among pediatric rheumatology patients receiving hydroxychloroquine.
AlAhmed O; Way A; Akoghlanian S; Barbar-Smiley F; Lemle S; MacDonald D; Frost E; Wise K; Lee L; Ardoin SP; Sivaraman V
Lupus; 2021 Feb; 30(2):269-279. PubMed ID: 33307983
[TBL] [Abstract][Full Text] [Related]
15. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy.
Marmor MF; Kellner U; Lai TY; Lyons JS; Mieler WF;
Ophthalmology; 2011 Feb; 118(2):415-22. PubMed ID: 21292109
[TBL] [Abstract][Full Text] [Related]
16. Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature.
Osadchy A; Ratnapalan T; Koren G
J Rheumatol; 2011 Dec; 38(12):2504-8. PubMed ID: 22002012
[TBL] [Abstract][Full Text] [Related]
17. Hydroxychloroquine-related retinal toxicity.
Ding HJ; Denniston AK; Rao VK; Gordon C
Rheumatology (Oxford); 2016 Jun; 55(6):957-67. PubMed ID: 26428520
[TBL] [Abstract][Full Text] [Related]
18. How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice.
Fairley JL; Nikpour M; Mack HG; Brosnan M; Saracino AM; Pellegrini M; Wicks IP
Intern Med J; 2023 Mar; 53(3):311-317. PubMed ID: 35969110
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus.
Vázquez-Otero I; Medina-Cintrón N; Arroyo-Ávila M; González-Sepúlveda L; Vilá LM
Lupus Sci Med; 2020 May; 7(1):. PubMed ID: 32434863
[TBL] [Abstract][Full Text] [Related]
20. Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy.
Abarientos C; Sperber K; Shapiro DL; Aronow WS; Chao CP; Ash JY
Expert Opin Drug Saf; 2011 Sep; 10(5):705-14. PubMed ID: 21417950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
